ClinicalTrials.gg

Program

Anti-CD39 Monoclonal Antibody IPH5201

Also written as “IPH5201 + durvalumab + standard chemotherapy” and “IPH5201”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 2, since Jan 7, 20202 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca10 open or runningphase 1since Jan 7, 2020Jan 7, 2020none ahead
Innate Pharma11 open or runningphase 2since Feb 15, 2023Feb 15, 2023Jun 2027phase 2 · NCT05742607
  • Named in AstraZeneca’s own pipeline as IPH5201, phase 2, as of Oct 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 7, 2020First study: phase 1 study in Advanced Solid TumorsNew to AstraZenecaAstraZeneca · NCT04261075 · 57 enrolled · United States, France, Spain and more
  2. Feb 15, 2023Innate Pharma’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Innate PharmaInnate Pharma · NCT05742607 · 70 planned · United States, France, Greece and more

Ahead

  1. Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungInnate Pharma · NCT05742607

TargetBeta

“A monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39 monoclonal antibody IPH5201 spec…”NCIt, read by Claude

Other programs on ENTPD1

ProgramCompanyFurthest phaseStudies
Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014ruleelpiscience-suzhou-biopharma-ltdphase 23
Anti-PD-1/Anti-CD39 Bispecific Antibody BNT317ruleBioNTechphase 21

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05742607Carcinoma, Non-Small-Cell Lung · United States, France, Greece and more2RecruitingInnate PharmaJun 202770
NCT04261075Advanced Solid Tumors · United States, France, Spain and more1CompletedAstraZenecaJun 16, 202257

How it is read

Names in the registry

  • “IPH5201 + durvalumab + standard chemotherapy”, 1 entry
  • “IPH5201”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.